You are here » Home » Companies » Company Overview » Jagsonpal Pharmaceuticals Ltd

Jagsonpal Pharmaceuticals Ltd.

BSE: 507789 Sector: Health care
NSE: JAGSNPHARM ISIN Code: INE048B01027
BSE 00:00 | 28 Sep 159.05 9.35
(6.25%)
OPEN

152.30

HIGH

171.00

LOW

152.25

NSE 00:00 | 28 Sep 159.15 9.60
(6.42%)
OPEN

150.40

HIGH

172.40

LOW

150.40

OPEN 152.30
PREVIOUS CLOSE 149.70
VOLUME 63973
52-Week high 203.25
52-Week low 35.45
P/E 19.49
Mkt Cap.(Rs cr) 417
Buy Price 0.00
Buy Qty 0.00
Sell Price 0.00
Sell Qty 0.00
OPEN 152.30
CLOSE 149.70
VOLUME 63973
52-Week high 203.25
52-Week low 35.45
P/E 19.49
Mkt Cap.(Rs cr) 417
Buy Price 0.00
Buy Qty 0.00
Sell Price 0.00
Sell Qty 0.00

Jagsonpal Pharmaceuticals Ltd. (JAGSNPHARM) - Company History

Promoted by J S Kochhar in 1978 Jagsonpal Pharmaceuticals is engaged in the manufacture and marketing bulk drugs and pharmaceuticals at its plant at Faridabad in Haryana. The company has adopted the strategy of clubbing all its products in seven groups for effective marketing and reducing costs. Simultaneously it has geared up to set up an ultra modern multi-purpose basic drugs and formulation plant through its subsidiary Jagsonpal Exports India Pvt Ltd.The company has a strategic alliance with Fidia Spa Italy; and B Spofola Czechoslovakia; to manufacture sophisticated drugs in India. It has tied up with another Israel-based company Makhteshim Chemical Works for acquiring the marketing rights of an anti-oxidant product. In 1994 the company has also promoted Aresco Financial Services a new financial company.The Company's R&D activities have resulted in manufacturing process upgradation improving packaging and cost containment. It's R&D activities are geared towards development of new product technologies which can be commercialised in future.It has tied up with Lycored Natural Products Industries (LNP) of Israel to launch a completely natural Lycopene bioactive product Lycored in India and SouthEast Asia.In the fiscal 2001 the company's sales grew by 15% to Rs 136.52 crore and the profit at the net level was up 8% to Rs 10.15 crore. This was achieved against heavy odds such as sluggish market trends lower growth rate of the industry and severe competition from drug majors. However the company has introduced various measures to counter the above factors so as to achieve continued growth and opportunity.

.